(0.34%) 5 117.15 points
(0.32%) 38 362 points
(0.38%) 15 988 points
(-0.88%) $83.11
(5.93%) $2.04
(0.41%) $2 356.80
(0.42%) $27.65
(3.87%) $957.75
(-0.22%) $0.933
(-0.38%) $10.98
(-0.55%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections...
Stats | |
---|---|
本日の出来高 | 14 623.00 |
平均出来高 | 90 731.00 |
時価総額 | 2.80M |
EPS | $0 ( 2024-01-01 ) |
次の収益日 | ( $0 ) 2024-06-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.390 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-18 | Hamilton John F | Buy | 15 000 | Stock Options |
2023-09-18 | Windham-bannister Susan Richards | Buy | 15 000 | Stock Options |
2023-09-18 | Patzer Eric | Buy | 15 000 | Stock Options |
2023-09-18 | Truong Vu | Buy | 30 000 | Stock Options |
2023-09-18 | Jafri Hasan | Buy | 20 000 | Stock Options |
INSIDER POWER |
---|
79.37 |
Last 96 transactions |
Buy: 1 744 135 | Sell: 1 215 301 |
Aridis Pharmaceuticals 相関
10 最も負の相関 | |
---|---|
NVDA | -0.954 |
CDNS | -0.949 |
NVCN | -0.947 |
UONE | -0.944 |
NVTS | -0.94 |
CMPO | -0.936 |
DKDCA | -0.936 |
SNPS | -0.934 |
LSCC | -0.933 |
STAY | -0.93 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Aridis Pharmaceuticals 財務諸表
Annual | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-1.640 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-1.640 |
FY | 2021 |
収益: | $1.54M |
総利益: | $1.54M (100.00 %) |
EPS: | $-0.0270 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.44 |
Financial Reports:
No articles found.
Aridis Pharmaceuticals
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。